QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer (NCT07636226) | Clinical Trial Compass
Not Yet RecruitingPhase 2/3
QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer
120 participantsStarted 2026-07-30
Plain-language summary
This is a multicenter, open-label, randomized controlled phase II/III study evaluating the efficacy and safety of QL1706 in combination with anlotinib as later-line treatment in patients with advanced lung cancer.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Absolute neutrophil count ≥ 1,500/mcL
. Platelet count \> 90,000/mcL
. Hemoglobin ≥ 9 g/dL (allowing for Hgb transfusion)
. Creatinine ≤ 1.5 × ULN
. Total bilirubin ≤ 1.5 mg/dL or ≤ 26 μmol/L
. If there is liver metastasis, AST (SGOT) / ALT (SGPT) ≤ 5 × ULN; if there is no liver metastasis, ≤ 2.5 × ULN
. Albumin ≥ 2.5 g/dL 12. Patients are allowed to receive palliative radiotherapy (such as radiotherapy after brain metastasis), provided that there are measurable target lesions in the radiation field of the patient.
. No hysterectomy or bilateral oophorectomy;
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is testing QL1706 combined with anlotinib as a later-line treatment — does that mean I would need to have already tried other treatments before I could even be considered, and how does that fit with where I currently am in my treatment journey?
2Since this is a Phase 2/3 trial and it hasn't started enrolling patients yet, what does that mean for how much safety and effectiveness data already exists for this specific combination in small cell lung cancer?
3The trial is measuring overall survival as its main goal — can you help me understand what that means practically, and how the results from this study might compare to what I could expect from standard treatment options available to me right now?
4Given that QL1706 is an immunotherapy and anlotinib targets blood vessel growth, are there specific risks or side effects from combining these two drugs that I should be aware of and discuss before considering this trial?
5Since the trial isn't recruiting yet, is it worth keeping this on our radar for the future, or are there other trials or standard treatments we should be focusing on in the meantime?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
OS
Timeframe: From date of first study treatment to date of death from any cause, assessed up to approximately 36 months